Your browser is no longer supported. Please, upgrade your browser.
Settings
INO Inovio Pharmaceuticals, Inc. daily Stock Chart
INO [NASD]
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.17 Insider Own1.60% Shs Outstand158.10M Perf Week9.00%
Market Cap3.68B Forward P/E18.25 EPS next Y1.28 Insider Trans-2.09% Shs Float154.65M Perf Month74.61%
Income-122.70M PEG- EPS next Q-0.17 Inst Own27.20% Short Float19.99% Perf Quarter187.93%
Sales2.60M P/S1414.94 EPS this Y-15.40% Inst Trans2.09% Short Ratio0.73 Perf Half Y654.19%
Book/sh1.48 P/B15.80 EPS next Y282.90% ROA-61.40% Target Price22.33 Perf Year697.95%
Cash/sh1.72 P/C13.63 EPS next 5Y0.00% ROE-178.40% 52W Range1.91 - 33.79 Perf YTD608.48%
Dividend- P/FCF- EPS past 5Y-14.60% ROI-137.90% 52W High-30.81% Beta1.47
Dividend %- Quick Ratio8.50 Sales past 5Y-17.00% Gross Margin- 52W Low1120.89% ATR3.13
Employees190 Current Ratio8.50 Sales Q/Q-53.60% Oper. Margin- RSI (14)57.13 Volatility10.43% 15.60%
OptionableYes Debt/Eq0.42 EPS Q/Q12.90% Profit Margin- Rel Volume0.40 Prev Close23.27
ShortableYes LT Debt/Eq0.42 EarningsMay 11 AMC Payout- Avg Volume42.52M Price23.38
Recom2.90 SMA2014.27% SMA5046.74% SMA200219.06% Volume16,799,838 Change0.47%
Jul-01-20Downgrade ROTH Capital Neutral → Sell $11
Jul-01-20Downgrade Maxim Group Buy → Hold
Jun-29-20Downgrade H.C. Wainwright Buy → Neutral
Jun-26-20Downgrade Stifel Buy → Hold $19 → $24
May-21-20Initiated The Benchmark Company Buy $28
Apr-30-20Downgrade ROTH Capital Buy → Neutral $13
Mar-13-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-13-20Downgrade Piper Sandler Overweight → Neutral
Dec-19-19Initiated ROTH Capital Buy $13
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Mar-16-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-16Initiated Aegis Capital Buy
Aug-09-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Stifel Buy $19 → $13
Jan-05-16Reiterated Maxim Group Buy $23 → $14
Jul-11-20 07:03AM  
Jul-10-20 09:48AM  
Jul-09-20 06:00AM  
Jul-08-20 05:50PM  
11:30AM  
06:49AM  
06:30AM  
Jul-07-20 08:05PM  
04:59AM  
Jul-06-20 02:50PM  
Jul-04-20 09:25AM  
08:09AM  
Jul-02-20 11:14AM  
07:01AM  
Jul-01-20 03:18PM  
01:11PM  
11:50AM  
11:19AM  
09:46AM  
Jun-30-20 08:37PM  
05:49PM  
02:30PM  
02:17PM  
12:41PM  
12:16PM  
11:52AM  
11:36AM  
11:24AM  
11:19AM  
10:04AM  
08:12AM  
08:04AM  
07:30AM  
Jun-29-20 02:06PM  
12:53PM  
10:37AM  
Jun-28-20 04:51PM  
02:23PM  
10:01AM  
Jun-27-20 01:16PM  
08:43AM  
Jun-26-20 04:19PM  
02:25PM  
11:09AM  
11:07AM  
08:46AM  
Jun-25-20 12:59PM  
12:52PM  
08:00AM  
Jun-24-20 11:24AM  
08:07AM  
Jun-23-20 09:34PM  
02:38PM  
09:50AM  
07:53AM  
07:45AM  
07:41AM  
07:30AM  
Jun-20-20 12:11PM  
Jun-19-20 06:43PM  
Jun-18-20 10:50PM  
Jun-17-20 06:10PM  
11:57AM  
Jun-16-20 12:42PM  
Jun-12-20 01:37PM  
Jun-10-20 02:22PM  
Jun-08-20 12:35PM  
Jun-05-20 03:21PM  
Jun-04-20 02:42PM  
06:00AM  
05:47AM  
Jun-03-20 03:51PM  
01:41PM  
Jun-02-20 04:47PM  
11:31AM  
May-31-20 12:23PM  
May-29-20 11:43AM  
May-28-20 11:34AM  
May-27-20 01:25PM  
May-26-20 05:38PM  
01:47PM  
11:53AM  
09:59AM  
08:00AM  
May-24-20 08:21AM  
May-22-20 09:42AM  
May-21-20 03:48PM  
02:52PM  
May-20-20 04:44PM  
03:02PM  
02:34PM  
12:15PM  
11:37AM  
10:21AM  
09:20AM  
08:51AM  
07:31AM  
07:28AM  
07:00AM  
May-19-20 03:18PM  
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIES PETERCFOJun 30Sale26.5035,000927,500119,290Jul 02 09:05 PM
Humeau LaurentChief Scientific OfficerJun 22Sale14.7019,467286,16563,433Jun 24 04:56 PM
BENITO SIMON XDirectorMay 20Option Exercise4.608,75040,25060,400May 20 05:37 PM
BENITO SIMON XDirectorMay 20Sale15.958,750139,59451,650May 20 05:37 PM
Weiner David B.DirectorMay 11Sale11.842,40428,463827,219May 12 04:26 PM
Weiner David B.DirectorMar 12Sale11.143,50038,990821,610Mar 12 04:40 PM
Weiner David B.DirectorMar 10Sale9.323,50032,620825,110Mar 12 04:40 PM
Weiner David B.DirectorMar 09Sale18.003,50063,000816,944Mar 09 04:20 PM
Kim Jong JosephChief Executive OfficerJan 13Buy3.1122,50069,9751,100,707Jan 13 12:10 PM
Humeau LaurentChief Scientific OfficerAug 30Buy2.224,5009,99050,333Sep 04 09:57 AM
Weiner David B.DirectorAug 01Sale2.7216,35244,477797,110Aug 02 05:00 PM